For Investors

Building the infrastructure layer for continuous, personalised chronic care in Europe.

Lyvup operates at the convergence of biosensors, AI, and behavioural science — developing platforms that pharmaceutical companies, clinicians, and health systems rely on to move chronic care from episodic to continuous. This page outlines our investment thesis and current status for qualified investors.

Thesis

Why we believe this is the right bet, at the right time.

Chronic care is structurally mis-served by episodic models.

Most chronic care protocols are designed around quarterly or biannual consultations. Clinically relevant signals change continuously. The gap between the periodic snapshot and the continuous reality is where adherence fails, where side-effects go undetected, and where expensive therapies go to patients who will not respond.

The convergence is happening now.

Non-invasive biosensors are reaching the accuracy thresholds required for clinical application. AI models can interpret multimodal physiological and behavioural data at a level not possible five years ago. Regulatory frameworks for digital therapeutics have matured across the EU. The pieces that had to exist separately now exist simultaneously — and the integration layer is still open.

Europe is the right market first.

Public health systems create clearer commercial pathways for evidence-backed digital therapeutics than fragmented US payer markets. DiGA in Germany, ZIN in the Netherlands, and parallel frameworks across other EU states provide a reimbursement route. European academic medical centres are, in our experience, more willing collaborators for the kind of clinical research this work requires.

Platform positioning is the defensible position.

We are not building a single application for a single condition. We are building the underlying infrastructure — where sensors, AI, and digital therapeutics integrate into a coherent layer that serves pharmaceutical companies, clinicians, and patients simultaneously. The moat is the integration itself, the clinical validation behind it, and the data it generates.

Founder-funded and grant-backed — by deliberate choice.

Lyvup has been built entirely on founder capital and competitively awarded research grants. No external equity has been taken. This was not a limitation — it was a decision.

The grants — a Horizon Europe programme in which Lyvup serves as Principal Investigator, and a ZonMW programme alongside Amsterdam UMC, TU Delft, TU Eindhoven, and the University of Amsterdam — are not soft money. They are competitively awarded to programmes that pass independent scientific review. They have funded the development and clinical validation work that now underpins the platform.

By reaching this point without dilution, Lyvup enters its first institutional raise with full founder equity intact, a functioning multi-programme research infrastructure, and a clear view of where capital creates leverage — rather than where it sustains operations.

What this means for investors

→ No cap table complexity. A clean, founder-held equity structure with no prior institutional investors, bridge notes, or convertible instruments to navigate.
→ Externally validated science. The research programmes were funded through independent competitive review — not internal conviction alone.
→ Aligned incentives. Founders who have backed the company with their own capital have the same interest in capital efficiency that institutional investors do.
→ Capital deployed for scale, not survival. The infrastructure exists. Investment goes into clinical validation, commercial deployment, and team — not into building what should have been built before raising.

The investors we work best with.

We are most productive in conversation with health tech-specialised venture funds, pharmaceutical corporate venture arms, and family offices with demonstrated patience for the timelines of clinical research. Our preferred structures preserve long-term platform independence — we have been deliberate about avoiding exclusivity arrangements with any single pharmaceutical partner, and this carries through to how we structure capital.

Contact

For qualified investors.

For fundraising-related conversations, please use our contact form and select "Investor" — include a brief note on your fund, investment focus, and what prompted the outreach. We reply to every qualified enquiry. For detailed materials, reference your data room request in the message.